Kallel H - Search Results

1

Development of a vectored vaccine against hepatitis E virus.

Trabelsi K, Kamen A, Kallel H. Trabelsi K, et al. Among authors: kallel h. Vaccine. 2014 May 19;32(24):2808-11. doi: 10.1016/j.vaccine.2014.02.041. Epub 2014 Feb 26. Vaccine. 2014. PMID: 24583005

2

Immunogenicity and efficacy of an in-house developed cell-culture derived veterinarian rabies vaccine.

Kallel H, Diouani MF, Loukil H, Trabelsi K, Snoussi MA, Majoul S, Rourou S, Dellagi K. Kallel H, et al. Vaccine. 2006 May 29;24(22):4856-62. doi: 10.1016/j.vaccine.2006.03.012. Epub 2006 Mar 20. Vaccine. 2006. PMID: 16600442

3

An animal component free medium that promotes the growth of various animal cell lines for the production of viral vaccines.

Rourou S, Ben Ayed Y, Trabelsi K, Majoul S, Kallel H. Rourou S, et al. Among authors: kallel h. Vaccine. 2014 May 19;32(24):2767-9. doi: 10.1016/j.vaccine.2014.02.040. Epub 2014 Feb 26. Vaccine. 2014. PMID: 24583007

4

Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials.

Kallel H, Kamen AA. Kallel H, et al. Biotechnol J. 2015 May;10(5):741-7. doi: 10.1002/biot.201400390. Epub 2015 Apr 24. Biotechnol J. 2015. PMID: 25914340 Review.

5

Purification of rabies virus produced in Vero cells grown in serum free medium.

Trabelsi K, Ben Zakour M, Kallel H. Trabelsi K, et al. Among authors: kallel h. Vaccine. 2019 Nov 8;37(47):7052-7060. doi: 10.1016/j.vaccine.2019.06.072. Epub 2019 Jul 9. Vaccine. 2019. PMID: 31300287 Free article.

6

Optimization of virus yield as a strategy to improve rabies vaccine production by Vero cells in a bioreactor.

Trabelsi K, Rourou S, Loukil H, Majoul S, Kallel H. Trabelsi K, et al. Among authors: kallel h. J Biotechnol. 2006 Jan 24;121(2):261-71. doi: 10.1016/j.jbiotec.2005.07.018. Epub 2005 Sep 8. J Biotechnol. 2006. PMID: 16153733

7

Development of a measles vaccine production process in MRC-5 cells grown on Cytodex1 microcarriers and in a stirred bioreactor.

Trabelsi K, Majoul S, Rourou S, Kallel H. Trabelsi K, et al. Among authors: kallel h. Appl Microbiol Biotechnol. 2012 Feb;93(3):1031-40. doi: 10.1007/s00253-011-3574-y. Epub 2011 Sep 21. Appl Microbiol Biotechnol. 2012. PMID: 21935589

8

Establishing a Robust Manufacturing Platform for Recombinant Veterinary Vaccines: An Adenovirus-Vector Vaccine to Control Newcastle Disease Virus Infections of Poultry in Sub-Saharan Africa.

Farnós O, Gelaye E, Trabelsi K, Bernier A, Subramani K, Kallel H, Yami M, Kamen AA. Farnós O, et al. Among authors: kallel h. Vaccines (Basel). 2020 Jun 26;8(2):338. doi: 10.3390/vaccines8020338. Vaccines (Basel). 2020. PMID: 32604755 Free PMC article.

9

Production and characterization of a fusion form of hepatitis E virus tORF2 capsid protein in Escherichia coli.

Boumaiza M, Trabelsi K, Choucha Z, Akrouti I, Leone S, Picone D, Kallel H. Boumaiza M, et al. Among authors: kallel h. Prep Biochem Biotechnol. 2021;51(6):562-569. doi: 10.1080/10826068.2020.1836656. Epub 2020 Oct 23. Prep Biochem Biotechnol. 2021. PMID: 33095097

10

A novel animal-component-free medium for rabies virus production in Vero cells grown on Cytodex 1 microcarriers in a stirred bioreactor.

Rourou S, van der Ark A, Majoul S, Trabelsi K, van der Velden T, Kallel H. Rourou S, et al. Among authors: kallel h. Appl Microbiol Biotechnol. 2009 Nov;85(1):53-63. doi: 10.1007/s00253-009-2064-y. Epub 2009 Jun 12. Appl Microbiol Biotechnol. 2009. PMID: 19521697

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

256 results

Search Page

Filters